top of page


From HTA results to guidance implementation: paving the way

  • Identify and categorise technologies offering prospects for efficiency gains outside incremental innovations (higher quality/higher costs)

  • Clarify under which conditions decremental cost-effectiveness is acceptable for collective health gains

  • Develop a tool-box for use at a local level for HTA projects to maximise those health gains

  • Systematic search of clinical trials registries and published literature to identify decrementally cost-effective programmes, as for example non-drug interventions or non-inferiority trials

  • Conduct a systematic enquiry into the willingness of stakeholders (namely patients, professionals, decision makers, tax payers) to accept a decremental efficacy

  • A toolbox and guidance for HTA agencies to go beyond cost-effective comparators in their assessments and recommendations


  • Deliverable D11.1: Systematic review of decrementally cost-effective interventions [PDF]

  • Deliverable D11.2: Stakeholders’ perspective: a political economy report [PDF]

  • Deliverable D11.3: A toolbox on candidate cost-effective technologies for HTA producers and users [PDF]

  • Work Package Overall Results [Poster PDF]

  • Budget impact analysis of triple therapy after failure of methotrexate for the treatment of rheumatoid arthritis in France – ISPOR Europe [weblink]

  • Annual cost of patients undergoing a total knee replacement in France – ISPOR Europe [weblink]


Paris School of Economics Hospital Innovation Economics (Hospinnomics)


Assistance Publique-Hôpitaux de Paris

Unité de Recherche Clinique en Économie de la Santé d’Ile de France (URC Eco)

Research team

Lise Rochaix (PI)

Isabelle Durand-Zaleski (PI)

Jean-Claude K. Dupont

Meryl Darlington

Emelie Lindström 

Ivan Tzintzun 

Jonathan Sicsic

Lucie Sabin

Rafaele Scarica

Xyomara Chavez Pacheco

Faustine Emmanuel

bottom of page